Pham, Anh N.Q.
Cummings, Michael
Yuksel, Nese
Sydora, Beate
Williamson, Tyler
Garies, Stephanie
Pilling, Russell
Lindeman, Cliff
Ross, Sue
Funding for this research was provided by:
Pfizer Quality Improvement Grant (60293977, 60293977)
Article History
Received: 21 December 2022
Accepted: 16 September 2023
First Online: 5 October 2023
Change Date: 19 October 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://0-doi-org.brum.beds.ac.uk/10.1186/s12911-023-02333-x
Declarations
:
: SR and NY received a research grant to fund this study (see below). NY has been on the advisory board and/or speaker for Biosyent, Bayer, Amgen, Organon and Duchesnay. All the remaining authors do not have any competing interest.
: This study has received approval from the Health Research Ethics Board at the University of Alberta (Pro00105443) and the University of Calgary (RES0051425) and adheres to all relevant guidelines and regulations for research involving de-identified health data (e.g. CHREB, Tri-Council Policy Statement on the Ethical Conduct for Research Involving Humans [TCPS2]). The CPCSSN database has received ethics approval, including waivers of individual patient informed consent for their de-identified data to be used for surveillance and research, from each contributing network’s local Research Ethics Board (Queen’s University, Memorial University of Newfoundland, University of Ottawa, University of Calgary, Dalhouse University, University of Toronto, Western University, Bruyère Research Institute, University of British Columbia, University of Alberta, and University of Manitoba).
: Not applicable.